24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Anchiano
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:41
"When should you buy? When there is panic": Investors weigh Wall Street rout
15:27
Fintech BridgeWise heads for IPO after losing $33 million in 18 months
14:49
The next Middle East power struggle is over internet cables, data and AI
14:36
Palo Alto in talks to acquire Israeli AI cyber startup Terra in deal that could exceed $500 million
More stories
Buzz
Most popular
Daily
Weekly
1
Colette Kress helped bring Israel to the heart of Nvidia's AI business. Now she's in charge.
2
CrowdStrike-Zscaler talks put two major Israeli cyber operations in focus
3
Cisco's latest layoffs could affect hundreds as workforce reduction continues
4
Intel has shed more than 50,000 employees since its 2022 workforce peak
5
Israeli startup receives FDA Breakthrough status for urine test targeting treatable dementia
More news
Anchiano
2 stories about Anchiano
Anchiano Therapeutics Schedules TASE Delisting
14.03.19
|
Lilach Baumer
Based in Jerusalem and Cambridge, Massachusetts, clinical-stage Anchiano develops gene therapies for cancer, with a special focus on bladder cancer
Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq
09.01.19
|
Lilach Baumer
The company formerly known as BioCanCell submitted a prospectus to the SEC on Monday, with Oppenheimer & Co. as the sole underwriter